J Geriatr Neurol > Volume 5(1); 2026 > Article
Nyirenda, Chihota, Bolaji, Forde, Stafford, Ashur, Bilchick, Phiri, Kabwe, Brewer, Mubanga, Mohammed, Breathett, Raju, Vidic, Mehta, Lin, Saylor, Addison, Kwon, and Mazimba: Estimated pulse wave velocity, dementia risk, and vascular aging phenotypes: a post-hoc analysis of the SPRINT-MIND trial in the United States

Abstract

Background

Vascular aging contributes to dementia risk, yet clinically interpretable markers for risk stratification remain limited. Estimated pulse wave velocity (ePWV), derived from age and mean arterial pressure, provides an accessible surrogate of arterial stiffness. We evaluated whether baseline ePWV identifies an interpretable threshold for probable dementia and distinct vascular aging phenotypes.

Methods

We conducted a post-hoc analysis of SPRINT-MIND including 8,536 participants free of dementia at baseline. Baseline ePWV was calculated using age and mean arterial pressure. The primary outcome was incident probable dementia adjudicated during follow-up. Associations between ePWV and dementia risk were assessed using spline-based and quartile-based Cox proportional hazards models. Model discrimination was evaluated using Harrell’s C-index.

Results

During follow-up, 323 participants developed probable dementia. Dementia risk was lowest at lower ePWV values and increased beyond approximately 10.7 m/s, identifying an interpretable risk threshold. Risk was concentrated in the highest ePWV quartile, consistent with a threshold-like pattern rather than a uniform linear gradient. In exploratory analyses, longitudinal clustering identified distinct ePWV trajectory phenotypes over 24 months.

Conclusions

Baseline ePWV identified an interpretable dementia risk threshold and distinct vascular aging phenotypes in SPRINT-MIND. These findings support ePWV as a clinically interpretable marker of vascular aging that may aid dementia risk stratification.

Introduction

Dementia is a leading global contributor to disability and mortality, affecting more than 55 million people worldwide, with prevalence rising sharply with age [1]. In the United States, an estimated 7.2 million adults aged ≥65 years are living with Alzheimer’s dementia in 2025 [2]. Despite extensive research, effective preventive strategies remain limited, underscoring the need to identify modifiable risk factors and accessible markers that predict future dementia risk [3,4].
There is increasing recognition that vascular factors contribute substantially to cognitive decline and dementia. Elevated blood pressure in midlife is one of the most consistent modifiable risk factors for dementia, associated with both cerebrovascular pathology and accelerated cognitive decline [5-7]. However, traditional blood pressure measures provide only a partial picture of the cumulative vascular burden and may not fully capture the hemodynamic stress imparted on the cerebral microvasculature over time.
Arterial stiffness, a hallmark of vascular aging, reflects the cumulative hemodynamic impact of aging, hypertension, and other vascular risk factors [8]. Carotid-femoral pulse wave velocity (cfPWV) is considered the gold standard for measuring arterial stiffness and has been associated with cognitive impairment, white matter hyperintensities, and dementia in observational studies [9-11]. Despite its prognostic value, widespread clinical or research use of cfPWV is limited by the need for specialized equipment and operator expertise.
Estimated pulse wave velocity (ePWV), derived from age and mean blood pressure, represents a practical and scalable alternative to cfPWV and has been associated with cardiovascular morbidity and mortality across diverse populations [12,13]. In the Systolic Blood Pressure Intervention Trial (SPRINT), ePWV was associated with cardiovascular outcomes and all-cause mortality [13]. Recent analyses from the SPRINT-MIND ancillary study also suggest that higher ePWV is linked to cognitive decline and combined cognitive outcomes, although interpretation has largely relied on conventional categorical contrasts [14].
Prior work has established associations between ePWV and cognitive outcomes [14]. However, clinically interpretable thresholds across the vascular aging spectrum and longitudinal vascular aging phenotypes remain poorly characterized. In this post-hoc analysis of SPRINT-MIND, we sought to identify nonlinear risk patterns, determine an interpretable ePWV threshold associated with probable dementia risk, and characterize longitudinal vascular aging trajectories.

Methods

1. Study design and population

This study was a post-hoc analysis of data from the SPRINT and its cognitive ancillary study, SPRINT-MIND. The design and primary results of SPRINT have been published previously [6,7]. Briefly, SPRINT was a multicenter, randomized clinical trial that enrolled adults aged ≥50 years with systolic blood pressure (SBP) ≥130 mmHg and increased cardiovascular risk, but without diabetes mellitus or prior stroke. Participants were randomized to intensive (target SBP <120 mmHg) or standard (target SBP <140 mmHg) blood pressure treatment.
SPRINT-MIND evaluated cognitive outcomes during trial follow-up using standardized assessments and adjudication procedures [8]. The present analysis included participants with available baseline blood pressure data required to derive ePWV and complete follow-up for incident probable dementia. The baseline analytic cohort comprised 8,536 participants, among whom 323 incident probable dementia events were observed. Baseline corresponded to the SPRINT randomization visit (2010-2013), and follow-up for adjudicated cognitive outcomes continued through July 22, 2018. For longitudinal trajectory analyses, we included participants with at least six scheduled study visits within the first 24 months of follow-up (n=8,321, 312 events).
ePWV was calculated at baseline using a validated equation incorporating age and mean arterial pressure (MAP), consistent with prior literature [15-18]. Higher ePWV values reflect greater arterial stiffness and advanced vascular aging. Baseline ePWV was defined as the value derived from blood pressure measurements obtained at the visit closest to randomization.
The primary outcome was incident probable dementia. Probable dementia was determined through standardized longitudinal cognitive assessments with blinded expert adjudication using prespecified SPRINT-MIND criteria (with panel review of uncertain cases) [8]. Time-to-event was defined from randomization to the first diagnosis of probable dementia, death, loss to follow-up, or administrative censoring, whichever occurred first.

2. Ethical approval

This study used de-identified data from the SPRINT and SPRINT-MIND trials. The original study protocols were approved by the institutional review boards at participating institutions, and all participants provided written informed consent. The present post-hoc analysis used de-identified data.

3. Covariates

Covariates were selected a priori based on clinical relevance and prior SPRINT-MIND analyses. These included sex (male/female), race and/or ethnicity (Black, White, Hispanic), smoking status (never/former/current), chronic kidney disease (yes/no), clinical cardiovascular disease (yes/no), subclinical cardiovascular disease (yes/no), and randomized treatment arm (intensive vs standard). Because ePWV is derived from age and MAP, age was not included in the primary multivariable models, consistent with prior studies evaluating vascular stiffness markers [14]. All covariates were assessed at baseline.

4. Statistical analysis

1) Baseline distribution and quartiles

Baseline ePWV was summarized using means, medians, and interquartile ranges. Participants were categorized into quartiles based on the distribution of baseline ePWV. Quartile cut points were derived empirically from the analytic cohort and used to facilitate clinical interpretability.

2) Association between baseline ePWV and probable dementia

Time-to-event analyses were conducted using Cox proportional hazards models. Baseline ePWV was examined using flexible spline-based modeling to evaluate the shape of the association across the baseline ePWV range and to identify interpretable features such as a risk nadir and threshold. Results from spline models were used descriptively to inform clinically interpretable contrasts.
To facilitate risk stratification, multivariable Cox models were then fit comparing quartiles of baseline ePWV, with the lowest quartile (Q1) serving as the reference group. Models were adjusted for sex, race and/or ethnicity, smoking status, chronic kidney disease, clinical cardiovascular disease, subclinical cardiovascular disease, and randomized treatment arm.

3) Prediction performance

To evaluate model discrimination across clinical, pulse pressure, and ePWV-based models, Harrell’s C-index was calculated. We compared a clinical model including established covariates with a model that additionally incorporated baseline ePWV. Differences in discrimination were summarized as absolute changes in the C-index.

4) Longitudinal trajectory analysis

As a secondary and exploratory analysis, longitudinal ePWV trajectories over the first 24 months of follow-up were characterized. For each participant, trajectory features including mean ePWV, slope, within-person variability, and net change were derived. Participants were clustered using unsupervised k-means clustering (k=3) to identify distinct vascular aging phenotypes.

5) Statistical software

All analyses were performed using R ver. 4.3.0 (R Foundation for Statistical Computing). Two-sided p-values <0.05 were considered statistically significant.

Results

The baseline analytic cohort included 8,536 participants (Table 1), among whom 323 incident probable dementia events occurred during follow-up. The mean±standard deviation baseline ePWV was 10.9±1.71, with a median (interquartile range) of 10.7 (2.43) and values ranging from 5.76 to 16.89. Participants were evenly distributed across quartiles of baseline ePWV (approximately 2,134 per quartile). Quartile cut points were <9.58 (Q1), 9.58-10.70 (Q2), 10.70-12.00 (Q3), and ≥12.00 (Q4). Median and mean ePWV values increased progressively across quartiles.
Spline-based Cox modeling was used to evaluate the association between baseline ePWV and incident probable dementia across the exposure range. Dementia risk was lowest at lower ePWV values, with a risk nadir near ePWV ≈8.6, and increased beyond approximately 10.7 m/s, indicating an interpretable risk threshold. Risk increased more steeply at higher ePWV levels, corresponding to the upper range of the distribution (Figure 1).
In the fully adjusted model (Table 2), dementia risk differed across quartiles of baseline ePWV. Compared with participants in the lowest quartile (Q1), those in the highest quartile (Q4) experienced substantially higher dementia risk, whereas risk differences in intermediate quartiles were more modest. These findings suggest that dementia risk was concentrated in the upper range of ePWV, consistent with a threshold-like pattern. Addition of pulse pressure modestly improved discrimination, whereas inclusion of baseline ePWV further improved model discrimination. These findings likely reflect the integrated vascular aging information captured by ePWV (Table 3). In sensitivity analyses including age, quartile-based associations were substantially attenuated, consistent with overlap between ePWV and age-related vascular aging processes. Similarly, addition of ePWV to models already including age and MAP did not meaningfully improve discrimination (C-index 0.764 vs. 0.764), reflecting shared vascular aging information between these variables.
Among 8,321 participants with at least six scheduled study visits within the first 24 months of follow-up, longitudinal ePWV trajectories were characterized using clustering. Three distinct vascular aging phenotypes were identified: decreasing, stable, and increasing ePWV trajectories (Figure 2).

Discussion

In this post-hoc analysis of SPRINT-MIND, baseline ePWV demonstrated a nonlinear relationship with probable dementia risk, with risk increasing beyond an interpretable threshold around 10.7 m/s. Dementia risk was concentrated in the upper range of ePWV, and exploratory trajectory analyses identified distinct vascular aging phenotypes over time. These findings extend prior work by emphasizing threshold identification and vascular aging patterns rather than re-establishing the association between ePWV and dementia.
Arterial stiffness reflects cumulative vascular injury and pulsatile hemodynamic stress, processes that are increasingly recognized as contributors to cerebral small vessel disease and neurodegeneration [19-21]. Although prior studies linked higher ePWV to adverse cognitive outcomes using conventional categorical contrasts [14], the clinical interpretation of these associations remain limited. By characterizing the association across the observed range of baseline ePWV, our findings suggest that dementia risk is not evenly distributed across ePWV values but instead increases most prominently beyond an empirically derived threshold. This may enhance the clinical interpretability of ePWV and support the use of ePWV in risk stratification. Because ePWV incorporates age and blood pressure in its derivation, it should be interpreted as an integrated marker of vascular aging rather than an isolated physiological measure. The threshold identified in this study therefore reflects a point along the vascular aging continuum at which dementia risk becomes more pronounced. Sensitivity analyses including age substantially attenuated quartile-based associations, which was expected given the derivation of ePWV from age and blood pressure.
The marked elevation in dementia risk observed in the highest ePWV quartile further supports the concept of risk concentration among individuals with advanced vascular aging. In contrast, intermediate ePWV quartiles demonstrated more modest risk differences relative to the lowest quartile, reinforcing the relevance of identifying individuals at the upper extreme of arterial stiffness rather than assuming a uniform risk gradient. These findings are consistent with mechanistic evidence linking excessive arterial stiffness to impaired cerebral autoregulation, increased pulsatile flow transmission, and microvascular damage [20,22,23].
Addition of baseline ePWV improved model discrimination beyond the clinical model and pulse pressure alone, likely reflecting the integrated vascular aging information captured by ePWV. These findings should be interpreted primarily within the context of risk stratification and threshold identification rather than independent predictive performance [24,25].
As a secondary and exploratory analysis, we identified distinct longitudinal ePWV trajectory phenotypes over the first 24 months of follow-up. These phenotypes illustrate heterogeneity in arterial stiffness progression, even within a randomized clinical trial setting. The lower proportion of participants assigned to intensive blood pressure treatment in the increasing ePWV phenotype is consistent with prior evidence that intensive blood pressure control attenuates vascular aging processes [26]. However, these findings should be interpreted descriptively, as trajectory clustering was not designed to evaluate causal treatment effects.
Our findings build upon and extend prior SPRINT-MIND analyses that reported associations between higher ePWV and cognitive outcomes [14]. Whereas earlier work emphasized categorical contrasts and composite cognitive endpoints, the present study focuses on probable dementia, introduces a threshold-based risk framework, and characterizes vascular aging phenotypes over time. Together, these features enhance the clinical translation of ePWV as a vascular aging marker.
Several limitations merit consideration. First, ePWV is a derived measure based on age and blood pressure rather than a direct measurement of arterial stiffness, which may introduce measurement error and could attenuate associations or shift the apparent risk threshold compared with directly measured carotid-femoral PWV. Second, the relatively low event rate for probable dementia limited power for some subgroup and trajectory analyses, increasing uncertainty and widening confidence intervals, such that smaller differences may have gone undetected. Third, trajectory clustering was exploratory and not optimized specifically for probable dementia separation, so misclassification of trajectory membership is possible and would be expected to bias associations toward the null. Finally, because this was a post-hoc analysis within a clinical trial cohort, external validation in other populations is needed; effect sizes and threshold values may differ in cohorts with different age distributions, comorbidity burden, or blood pressure measurement protocols.
Strengths of this study include the use of a large, well-characterized randomized trial cohort with standardized blood pressure measurement procedures and systematic longitudinal follow-up. Cognitive outcomes were adjudicated using prespecified SPRINT-MIND criteria by blinded experts, reducing outcome misclassification. We applied complementary analytic approaches, including spline-based modeling to identify an interpretable risk threshold, quartile-based contrasts for clinical interpretability, and discrimination analyses, to provide convergent evidence for the association between ePWV and probable dementia risk. Finally, exploratory trajectory analyses leveraged repeated early follow-up measurements to characterize heterogeneity in vascular aging patterns.
In conclusion, baseline ePWV identified an interpretable dementia risk threshold in SPRINT-MIND, with risk concentrated at higher levels of vascular aging. Exploratory longitudinal analyses further identified distinct vascular aging phenotypes over time. Together, these findings support the role of ePWV as a clinically interpretable marker of vascular aging that may aid in dementia risk stratification and communication.

Notes

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Funding

This research was supported [in part] by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH author(s) are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or U.S. Department of Health and Human Services.

Author Contributions

Conceptualization: SM; Formal analysis: NN; Investigation: BC, OB, ATF, PS, NA, KCB, JP, JCK, LCB, MM, SFM, KB, MR, AV, NM, EL, DS, DA, YK, SM; Resources: SM; Methodology: SM; Project administration: SM; Supervision: SM; Validation: SM, ATF, YK; Writing-original draft: NN, SM, OB; Writing-review & editing: all authors.

Figure 1.
Association between baseline estimated pulse wave velocity (ePWV) and risk of probable dementia modeled using spline-based Cox regression.
jgn-2026-00227f1.jpg
Figure 2.
Longitudinal estimated pulse wave velocity (ePWV) trajectory phenotypes over 24 months.
jgn-2026-00227f2.jpg
Table 1
Baseline characteristics by quartiles of baseline ePWV
Characteristic Q1 (lowest) (n=2,135) Q2 (n=2,134) Q3 (n=2,133) Q4 (highest) (n=2,134) p-value
Baseline ePWV (m/s) 8.81±0.61 10.13±0.31 11.32±0.39 13.16±0.92 <0.001
Age (yr) 58.4±4.7 63.8±5.0 70.3±5.7 79.1±5.4 <0.001
Systolic BP (mmHg) 120.76±11.48 130.14±12.20 133.36±14.75 138.03±15.34 <0.001
Diastolic BP (mmHg) 72.19±9.41 75.81±10.66 73.44±12.80 71.15±11.67 <0.001
Mean arterial pressure (mmHg) 91.62±9.14 97.55±9.96 97.41±12.41 97.90±11.48 <0.001
Pulse pressure (mmHg) 48.58±9.65 54.33±10.87 59.92±11.42 66.88±13.54 <0.001
Sex 0.008
 Male 1,403 (65.7) 1,433 (67.2) 1,371 (64.3) 1,330 (62.3)
 Female 732 (34.3) 701 (32.8) 762 (35.7) 804 (37.7)
Race/ethnicity <0.001
 Black 925 (43.3) 712 (33.4) 588 (27.6) 428 (20.1)
 White 901 (42.2) 1,176 (55.1) 1,358 (63.7) 1,566 (73.4)
 Hispanic 309 (14.5) 246 (11.5) 187 (8.8) 140 (6.6)
Smoking status <0.001
 Never 934 (43.7) 905 (42.4) 917 (43.0) 1,020 (47.8)
 Former 703 (32.9) 892 (41.8) 1,033 (48.4) 1,040 (48.7)
 Current 498 (23.3) 337 (15.8) 183 (8.6) 74 (3.5)
Chronic kidney disease <0.001
 No 1,769 (82.9) 1,661 (77.8) 1,487 (69.7) 1,239 (58.1)
 Yes 366 (17.1) 473 (22.2) 646 (30.3) 895 (41.9)
Clinical cardiovascular disease <0.001
 No 1,736 (81.3) 1,774 (83.1) 1,681 (78.8) 1,643 (77.0)
 Yes 399 (18.7) 360 (16.9) 452 (21.2) 491 (23.0)
Subclinical cardiovascular disease <0.001
 No 1,825 (85.5) 1,845 (86.5) 1,749 (82.0) 1,704 (79.9)
 Yes 310 (14.5) 289 (13.5) 384 (18.0) 430 (20.1)
Treatment arm <0.001
 Intensive 1,225 (57.4) 1,012 (47.4) 1,055 (49.5) 975 (45.7)
 Standard 910 (42.6) 1,122 (52.6) 1,078 (50.5) 1,159 (54.3)

Values are mean±standard deviation or number (%).

ePWV, estimated pulse wave velocity; BP, blood pressure.

p-values are from Kruskal-Wallis tests for continuous variables and Pearson χ² tests for categorical variables.

Table 2
Distribution of dementia risk across baseline ePWV quartiles
Baseline ePWV quartile Adjusted HR (95% CI) p-value
Q2 vs. Q1 1.62 (0.94-2.77) 0.08
Q3 vs. Q1 3.57 (2.20-5.78) <0.001
Q4 (highest) vs. Q1 10.86 (6.88-17.16) <0.001
Sensitivity model including age
 Q2 vs. Q1 0.90 (0.54-1.48) 0.676
 Q3 vs. Q1 0.59 (0.34-1.01) 0.054
 Q4 vs. Q1 0.92 (0.49-1.72) 0.803

Risk estimates should be interpreted in the context of the nonlinear spline analysis, which demonstrated concentration of risk at higher ePWV levels consistent with a threshold-like pattern. Sensitivity analyses including age are shown for transparency given the derivation of ePWV from age and blood pressure.

ePWV, estimated pulse wave velocity; HR, hazard ratio; CI, confidence interval.

Table 3
Model discrimination for incident probable dementia across clinical, PP, and ePWV models
Model C-index (SE)
Clinical model 0.630 (0.017)
Clinical+PP 0.686 (0.016)
Clinical+ePWV spline 0.787 (0.013)
Age+mean arterial pressure 0.764
Age+mean arterial pressure+ePWV 0.764

Clinical model includes sex, race/ethnicity, smoking status, chronic kidney disease, clinical cardiovascular disease, subclinical cardiovascular disease, and randomized treatment arm. The ePWV spline model additionally includes baseline ePWV modeled using a natural cubic spline (df=3). Additional sensitivity models including age and mean arterial pressure are shown to evaluate overlap in vascular aging information captured by ePWV.

PP, pulse pressure; ePWV, estimated pulse wave velocity; SE, standard error.

References

1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022;7:e105-e125.
crossref pmid pmc
2. 2025 Alzheimer’s disease facts and figures. Alzheimers Dement 2025;21:e70235.
crossref pmc
3. Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024;404:572-628.
crossref pmid pmc
4. Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, et al. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. Hypertension 2020;76:217-225.
crossref pmid
5. Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA 2020;323:1934-1944.
crossref pmid pmc
6. SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116.
crossref pmid pmc
7. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials 2014;11:532-546.
crossref pmid pmc pdf
8. SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA 2019;321:553-561.
crossref pmid pmc
9. Alvarez-Bueno C, Cunha PG, Martinez-Vizcaino V, Pozuelo-Carrascosa DP, Visier-Alfonso ME, Jimenez-Lopez E, et al. Arterial stiffness and cognition among adults: a systematic review and meta-analysis of observational and longitudinal studies. J Am Heart Assoc 2020;9:e014621.
crossref pmid pmc
10. van Sloten TT, Protogerou AD, Henry RM, Schram MT, Launer LJ, Stehouwer CD. Association between arterial stiffness, cerebral small vessel disease and cognitive impairment: a systematic review and meta-analysis. Neurosci Biobehav Rev 2015;53:121-130.
crossref pmid pmc
11. Liu Q, Fang J, Cui C, Dong S, Gao L, Bao J, et al. Association of aortic stiffness and cognitive decline: a systematic review and meta-analysis. Front Aging Neurosci 2021;13:680205.
crossref pmid pmc
12. Laugesen E, Olesen KKW, Peters CD, Buus NH, Maeng M, Botker HE, et al. Estimated pulse wave velocity is associated with all-cause mortality during 8.5 years follow-up in patients undergoing elective coronary angiography. J Am Heart Assoc 2022;11:e025173.
crossref pmid pmc
13. Vlachopoulos C, Terentes-Printzios D, Laurent S, Nilsson PM, Protogerou AD, Aznaouridis K, et al. Association of estimated pulse wave velocity with survival: a secondary analysis of SPRINT. JAMA Netw Open 2019;2:e1912831.
crossref pmid pmc
14. Hao P, Feng S, Suo M, Wang S, Zheng K, Wu X. Estimated pulse wave velocity and cognitive outcomes: a post hoc analysis of SPRINT-MIND. Am J Hypertens 2024;37:485-492.
crossref pmid pdf
15. Greve SV, Blicher MK, Kruger R, Sehestedt T, Gram-Kampmann E, Rasmussen S, et al. Estimated carotid-femoral pulse wave velocity has similar predictive value as measured carotid-femoral pulse wave velocity. J Hypertens 2016;34:1279-1289.
crossref pmid
16. Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010;31:2338-2350.
crossref pmid pmc
17. Greve SV, Laurent S, Olsen MH. Estimated pulse wave velocity calculated from age and mean arterial blood pressure. Pulse (Basel) 2017;4:175-179.
crossref pmid pmc pdf
18. Boutouyrie P. Estimating is not measuring: the lessons about estimated pulse wave velocity. J Am Heart Assoc 2022;11:e025830.
crossref pmid pmc
19. Zhai FF, Ye YC, Chen SY, Ding FM, Han F, Yang XL, et al. Arterial Stiffness and Cerebral Small Vessel Disease. Front Neurol 2018;9:723.
crossref pmid pmc
20. Mitchell GF, van Buchem MA, Sigurdsson S, Gotal JD, Jonsdottir MK, Kjartansson Ó, et al. Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility--Reykjavik study. Brain 2011;134:3398-3407.
crossref pmid pmc
21. Reeve EH, Barnes JN, Moir ME, Walker AE. Impact of arterial stiffness on cerebrovascular function: a review of evidence from humans and preclincal models. Am J Physiol Heart Circ Physiol 2024;326:H689-H704.
crossref pmid pmc
22. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005;46:200-204.
crossref pmid
23. Scheuermann BC, Parr SK, Schulze KM, Kunkel ON, Turpin VG, Liang J, et al. Associations of cerebrovascular regulation and arterial stiffness with cerebral small vessel disease: a systematic review and meta-analysis. J Am Heart Assoc 2023;12:e032616.
crossref pmid pmc
24. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
crossref pmid
25. Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 2011;30:1105-1117.
crossref pmid pmc pdf
26. Upadhya B, Pajewski NM, Rocco MV, Hundley WG, Aurigemma G, Hamilton CA, et al. Effect of intensive blood pressure control on aortic stiffness in the SPRINT-HEART. Hypertension 2021;77:1571-1580.
crossref pmid pmc


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#1111, Daeil Bldg, 12, Insadong-gil, Jongno-gu, Seoul 03163, Korea
Tel: +82-2-720-3982    E-mail: editor@e-jgn.org                

Copyright © 2026 by Korean Society of Geriatric Neurology.

Developed in M2PI

Close layer
prev next